Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) – Corneal Ulcer Pipeline Analysis Demonstrates New Therapies on the Horizon That Should Transform the Treatment Paradigm | SearchInsight
The majority of corneal ulcer drugs are in the early stages of development and in the coming years the market is expected to grow.
DelveInsight’s ‘Corneal ulcer pipeline overview‘ The report provides the current therapeutic landscape and a rich analysis of ongoing therapies at different stages of development, from preclinical to late stage, as well as dormant, inactive and abandoned therapeutic agents.
Some of the key points of the Corneal ulcer pipeline report:
- The Corneal Ulcer Pipeline report offers a rich analysis of 6+ key pharmaceutical companies and 6+ key therapies.
- The corneal ulcer pipeline includes therapies at different stages of testing such as SREC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, among others.
- Leading pharmaceutical companies working on corneal ulcer pipeline robustness include Recordati / Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, among others.
- FDA granted Orphan drug designation to the experimental product Recordati Rare Diseases REC 0559 for the treatment of neurotrophic keratitis.
Find out more about the pharmaceutical company and the therapy expected to gain maximum share by requesting a sample report @ Emerging therapies and predictions for corneal ulcer
Corneal ulcer: overview
Corneal ulcer, also known as keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma.
Although the treatment of refractory corneal ulcers is difficult, it is essential that they be resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea.
To learn more about the disease outlook, available therapies, and emerging medications, visit Corneal ulcer pipeline analysis
Corneal ulcer drug pipeline assessment
|REC 0559||Recording technique / Mime||Phase II||Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists||Eye drops solution|
|OC01||Oyster Point Pharmacy||Preclinical||Alpha4 beta2 nicotinic receptor agonists||N / A|
|CSB-001||Claris Biotherapeutics||Phase I / II||N / A||Ophthalmic solution|
|BD-111||Shanghai BDgene||Phase I / II||Mechanism not defined||corneal injection|
|NRO-1||Neuroptika||Phase I||Neurotrophic factor agonists derived from the glial cell line||Topical|
|Rose bengal sodium||Provectus Biopharmaceuticals||Preclinical||Cell death stimulants; Cell membrane modulators; Stimulants of dendritic cells; Immunostimulants; interferon modulators; interleukin 17 modulators; Interleukin-22 modulators||Topical|
Sample request to find out more @ Corneal Ulcer Pipeline Analysis, Key Companies and Futuristic Trends
Therapeutic evaluation of corneal ulcer
The Corneal Ulcer Pipeline report presents comprehensive coverage of active pipeline candidates segmented by stage, product type, route of administration (RoA), molecule type, target and mechanism of action (MoA).
By product type
- Phase I
- Phase II
- Phase III
By molecule type
- Monoclonal antibody
- Small molecule
- Genetical therapy
- type of product
By route of administration
- Molecule type
By mechanism of action
- Nerve growth factor receptor agonists
- Neurotrophic factor agonists derived from the glial cell line
- Alpha4 beta2 nicotinic receptor agonists
- Autophagy inhibitors
- Cell membrane modulators
- Autophagy inhibitors
- Nerve growth factor receptor
- Neurotrophic factor derived from the glial cell line
- Nicotinic receptor alpha4 beta2
Connect with our Business Executive to Asset prioritization services and advisory solutions
Scope of the Corneal Ulcer Pipeline Report
Key players: Recordati / Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen SAS, FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Medicine Therapeutics, AmebaGone, Inc. other.
Key pipeline therapies for corneal ulcer: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium and others.
Go to @ Corneal ulcer pipeline: new therapies and emerging technologies
|1||Presentation of the report|
|2||Overview of corneal ulcer|
|3||Corneal ulcer pipeline therapy|
|5||Corneal Ulcer – Analytical Perspective from DelveInsight|
|6||In-depth business assessment|
|7||Corneal ulcer collaboration offers|
|8||Therapeutics for corneal ulcer in clinical stage|
|9||Non-clinical corneal ulcer therapeutics|
|ten||Analysis of the therapeutic pipeline against corneal ulcer|
|11||Inactive Corneal Ulcer Pipeline Products|
|12||Key Corneal Ulcer Companies|
|13||Key products for corneal ulcer|
|14||Corneal Ulcer – Unmet Needs|
|15||Corneal Ulcer Market Drivers and Barriers|
|16||Corneal Ulcer – Future Perspectives and Conclusion|
|17||Corneal ulcer analyst opinions|
|19||Methodology of the report|
Learn more about the reporting offerings @ Ongoing therapies, treatments and clinical trials for corneal ulcer
Corneal ulcer market
DelveInsight’s “Corneal Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.
Peptic Ulcer Bleeding Market
DelveInsight’s “Peptic Ulcerative Hemorrhage – Market Overview, Epidemiology and Market Forecast-2030” report.
Varicose Ulcer Market
DelveInsight’s “Varicose Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.
Venous Leg Ulcer Market
DelveInsight’s “Venous Leg Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.
Global burden of cytomegalovirus seroprevalence
Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte and others.
DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical market research reports through our subscription platform PharmaDelve.
For more information visit Pharmaceutical, medical and biotechnology news